You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Three and 5-year data in all, operable, and inoperable patients

From: Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study

  All patients (n = 71) Operable patients (n = 24) Inoperable patients (n = 47) p-valuea
OS (%) at 3/5 years 73/65 71/66 74/65 0.78
PFS (%) at 3/5 years 64/55 58/49 68/60 0.61
Cumulative incidence of LR (%) at 3/5 years 12/15 17/21 9/12 0.34
  1. OS Overall survival, PFS Progression-free survival, LR Local recurrence
  2. aDifference between operable and inoperable patients